Oliclinomel N7-1000e (Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin)

Oliclinomel N7-1000e is an amino acid solution used in parenteral nutrition to support protein synthesis and nitrogen balance.

• Parenteral nutrition for patients unable to receive enteral feeding: supplies a complete amino acid profile to maintain nitrogen balance.
• Post‑operative or trauma patients requiring amino acid supplementation: supports wound healing and muscle recovery.
• Critical care patients with increased protein needs: helps meet elevated metabolic demands during intensive care.

• The solution delivers a balanced mixture of essential and non‑essential amino acids directly into the bloodstream. Cells take up these amino acids via transporters, incorporating them into nascent proteins and supporting tissue repair, enzyme production, and metabolic functions. By providing substrates for protein synthesis, the formulation helps maintain nitrogen balance and supports the heightened anabolic requirements of critically ill or surgically stressed patients.

Adverse reactions may occur with intravenous amino acid solutions and should be monitored.

Common Side Effects

• Infusion site erythema or pain: mild local irritation during administration.
• Nausea or vomiting: transient gastrointestinal discomfort.
• Transient hyperammonemia: mild elevation of blood ammonia levels.
• Mild electrolyte disturbances: changes in serum potassium or calcium.
• Low‑grade fever: temporary rise in body temperature.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical intervention.
• Metabolic acidosis: significant pH imbalance in blood.
• Hyperglycemia: marked increase in blood glucose levels.
• Renal dysfunction: impaired kidney function in susceptible patients.
• Hepatic dysfunction: liver enzyme elevations indicating stress.
• Thrombophlebitis: inflammation of veins at the infusion site.

When using Oliclinomel N7-1000e, clinicians should consider several safety measures.

• Renal impairment: monitor renal function and adjust infusion rate as needed.
• Hepatic dysfunction: assess liver enzymes before and during therapy.
• Electrolyte balance: check serum electrolytes regularly to detect shifts.
• Metabolic disorders: watch for signs of hyperammonemia or acidosis.
• Allergy: discontinue infusion immediately if hypersensitivity reactions develop.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Amino acid solutions can interact with other intravenous therapies and systemic medications.

Major Interactions (Avoid)

• Concurrent high‑dose amino acid solutions: risk of nitrogen overload and metabolic imbalance.
• Incompatible IV solutions (e.g., calcium chloride): may precipitate and cause catheter blockage.
• Certain chemotherapeutic agents: can alter amino acid metabolism and increase toxicity.

Moderate Interactions (Monitor Closely)

• Insulin or hypoglycemic agents: may require dose adjustment due to glucose fluctuations.
• Diuretics: can affect electrolyte status and necessitate monitoring.
• Renal replacement therapy: may remove administered amino acids, reducing efficacy.